Encouraging the prescribing of SGLT2i and GLP-1RA medications to reduce cardiovascular and renal risk in patients with type 2 diabetes: rationale and design of a randomized controlled trial.
作者：Nancy Haff [1];Daniel M Horn [2];Gauri Bhatkhande [3];Meekang Sung [4];Caitlin Colling [5];Wendy Wood [6];Ted Robertson [7];Daniel Gaposchkin [8];Leigh Simmons [9];Judy Yang [10];James Yeh [11];Katherine L. Crum [12];Kaitlin E. Hanken [13];Julie C. Lauffenburger [14];Niteesh K. Choudhry [15];
DOI：10.1016/j.ahj.2025.02.007